Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 11/20 | 0.44 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BPTF | Q12830 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2550526 | 0.81 | ALDH1A1 (0.58) | ALDH1A1PKMNPC1KAT2BBRD9 | |
| SCHEMBL2547161 | 0.80 | ALDH1A1 (0.60) | ALDH1A1PKMNPC1KAT2BBRD9 | |
| SCHEMBL2549761 | 0.80 | RAB9A (0.59) | ALDH1A1PKMNPC1KAT2BBRD9 | |
| SCHEMBL23573420 | 0.79 | RAB9A (0.44) | PKMNPC1RAB9AGAA | |
| SCHEMBL23573405 | 0.79 | RAB9A (0.47) | PKMNPC1RAB9AGAA | |
| SCHEMBL23573513 | 0.79 | GAA (0.44) | PKMRAB9AGAA | |
| SCHEMBL20831802 | 0.78 | ALDH1A1 (0.56) | ALDH1A1PKMNPC1KAT2BBRD9 | |
| SCHEMBL23573415 | 0.77 | RAB9A (0.45) | NPC1RAB9AGAA | |
| SCHEMBL9124077 | 0.77 | PKM (0.54) | ALDH1A1PKMNPC1KAT2BBRD9 | |
| SCHEMBL23573282 | 0.76 | RAB9A (0.47) | ALDH1A1PKMNPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | ALDH1A1 216/4885PKM 2686/4885NPC1 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.